Skip to main content

Table 3 New-onset dyslipidemia, diabetes mellitus and hypertension in the multiple myeloma and in the smoldering multiple myeloma patient groups compared to the control group

From: Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma

New-onset disease Study group HRa study/control 95% CI P-value
Dyslipidemia
 1-year FU MM 2.1 1.38–3.27 .001
SMM 1.9 1.14–3.14 .013
 3-year FU MM 4.7 2.32–9.61 <.001
SMM 4.2 1.87–9.61 .001
 5-year FU MM 2.9 1.54–5.45 .001
SMM 2.4 1.09–5.37 .029
DM
 1-year FU MM 2.7 1.17–6.12 .020
SMM 2.0 0.76–5.13 .165
 3-year FU MM 1.3 0.58–2.81 .547
SMM 1.0 0.36–2.97 .952
 5-year FU MM 2.1 0.85–5.07 .107
SMM 1.8 0.57–5.39 .324
Hypertension
 1-year FU MM 1.3 0.90–1.97 .151
SMM 1.3 0.80–2.05 .306
 3-year FU MM 1.1 0.72–1.80 .575
SMM 1.3 0.71–2.23 .432
 5-year FU MM 2.8 1.49–5.25 .001
SMM 2.2 0.95–4.96 .068
  1. aHazard ratio adjusted for age, sex, follow-up duration, and the presence of dyslipidemia, diabetes, and hypertension at study entry
  2. MM multiple myeloma, SMM smoldering multiple myeloma, FU follow-up, DM diabetes mellitus, CI confidence interval